Business Context and Reporting Period
Aimei Health Technology Co., Ltd. (AFJK) is a Cayman Islands exempted company operating as a Special Purpose Acquisition Company (SPAC). The company was incorporated on April 27, 2023, and consummated its Initial Public Offering (IPO) on December 6, 2023. The reporting period covers the fiscal year ended December 31, 2024. The company has no active operations other than identifying and evaluating target businesses for a merger. It is currently in the process of a proposed business combination with United Hydrogen Group Inc., entered into on June 19, 2024.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | Value |
|---|---|
| Revenue | $0 (No operating revenue) |
| Net Income | $2,552,215 |
| Interest Income (Trust Account) | $3,617,001 |
| Formation & Operating Costs | $(1,064,786) |
| Cash (Operating) | $28,208 |
| Cash Held in Trust Account | $73,784,549 |
| Working Capital Deficit | $(786,610) |
| Total Liabilities | $1,506,994 |
| Deferred Underwriting Fee | $690,000 |
| Shares Outstanding (Public) | 6,900,000 (Subject to redemption) |
Material Changes vs. Prior Period
- Net Income Surge: Net income increased from $171,389 in 2023 to $2,552,215 in 2024, driven primarily by higher interest income earned on the Trust Account ($3.6M vs. $0.2M) due to prevailing interest rates.
- Operating Costs: Formation and operating costs increased significantly to $1,064,786 in 2024 from $28,459 in 2023, reflecting ongoing due diligence and administrative expenses related to the proposed merger.
- Trust Account Balance: The Trust Account balance grew from $69,889,848 to $73,784,549, an increase of approximately $3.9M, attributable to interest earnings and extension payments deposited by the Sponsor and United Hydrogen.
- Liabilities: Current liabilities increased to $816,994 from $24,841, primarily due to the accrual of extension loans ($227,700) and amounts due to related parties ($289,780).
Guidance, Outlook, and Risks
Business Combination Status: The company has entered a definitive agreement to merge with United Hydrogen. The deadline to consummate the transaction has been extended to April 6, 2025. The Sponsor and United Hydrogen have deposited extension fees totaling $755,400 (four monthly payments) to extend the deadline.
Redemptions: In a subsequent event (February 2025), approximately 2,904,267 shares were redeemed at roughly $10.77 per share, totaling approximately $31.27 million. This significantly reduces the cash available in the Trust Account for the merger.
Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern if the business combination is not completed by the deadline. If the merger fails, the company will liquidate and distribute Trust Account funds to shareholders.
Internal Controls: Management identified a material weakness in internal controls over financial reporting as of December 31, 2024, citing inadequate segregation of duties and insufficient written policies due to limited personnel.
Risks: Key risks include the failure to close the United Hydrogen merger, potential bankruptcy claims against the Trust Account, and the inability of the Sponsor to satisfy indemnification obligations if third-party claims reduce Trust Account balances below $10.10 per share.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of shareholder approvals for both Aimei Health and United Hydrogen, as well as regulatory approvals (including CSRC).
- Trust Account Liquidity: Confirm the current cash balance in the Trust Account post-redemptions and ensure it meets the $5,000,001 net tangible asset requirement for closing.
- Extension Funding: Monitor whether the Sponsor and United Hydrogen continue to deposit the required monthly extension fees ($150,000/month) to maintain the April 6, 2025 deadline.
- Internal Control Remediation: Assess the company's plan to remediate the material weakness in internal controls prior to the merger closing.
- Deferred Fees: Confirm the treatment of the $690,000 deferred underwriting fee and whether it will be paid upon closing or waived if the deal fails.